Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04GNG
|
|||
| Drug Name |
CC-90011
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | ||
| Company |
CelgeneSummit, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lysine-specific histone demethylase 1 (LSD) | Target Info | Inhibitor | [1] |
| Pathway Interaction Database | Notch signaling pathway | |||
| Coregulation of Androgen receptor activity | ||||
| Notch-mediated HES/HEY network | ||||
| Reactome | HDACs deacetylate histones | |||
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | ||||
| Factors involved in megakaryocyte development and platelet production | ||||
| WikiPathways | Factors involved in megakaryocyte development and platelet production | |||
| Androgen receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.